Related references
Note: Only part of the references are listed.One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress
Mathijs C. Bunck et al.
ATHEROSCLEROSIS (2010)
Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice
Jacqueline F. Aitken et al.
DIABETES (2010)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
Ralph A. DeFronzo et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
T. Vilsboll et al.
DIABETIC MEDICINE (2008)
Guideline for management of postmeal glucose
Antonio Ceriello et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2008)
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Helle Linnebjerg et al.
REGULATORY PEPTIDES (2008)
Reduced incretin effect in type 2 diabetes - Cause or consequence of the diabetic state?
Filip K. Knop et al.
DIABETES (2007)
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
Dennis Kim et al.
DIABETES CARE (2007)
Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
Tina Vilsboll
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Gastric emptying: a comparison of three methods
Henning Glerup et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2007)
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Tina Vilsboll et al.
DIABETES CARE (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes
M. A. Nauck et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2006)
Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: Relationships with postprandial glycemic and insulinemic responses
TJ Little et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
JJ Meier et al.
DIABETOLOGIA (2006)
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
J Schirra et al.
GUT (2006)
Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
OG Kolterman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes
JJ Meier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients -: Variations with increasing levels of HbA1c
L Monnier et al.
DIABETES CARE (2003)
The influence of GLP-1 on glucose-stimulated insulin secretion -: Effects on β-cell sensitivity in type 2 and nondiabetic subjects
LL Kjems et al.
DIABETES (2003)
A longitudinal study of gastric emptying and upper gastro intestinal symptoms in patients with diabetes mellitus
KL Jones et al.
AMERICAN JOURNAL OF MEDICINE (2002)
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes
CB Juhl et al.
DIABETES (2002)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
Effects of glucagon-like peptide-1 (7-36)amide on motility and sensation of the proximal stomach in humans
J Schirra et al.
GUT (2002)
How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study
M Willems et al.
DIGESTIVE DISEASES AND SCIENCES (2001)
A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans
C Verdich et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Effects of glucagon-like peptide-1 (7-36) amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans
J Schirra et al.
GUT (2000)